Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

A transition-edge sensor-based x-ray spectrometer for the study of highly charged ions at the National Institute of Standards and Technology electron beam ion trap.

Szypryt P, O'Neil GC, Takacs E, Tan JN, Buechele SW, Naing AS, Bennett DA, Doriese WB, Durkin M, Fowler JW, Gard JD, Hilton GC, Morgan KM, Reintsema CD, Schmidt DR, Swetz DS, Ullom JN, Ralchenko Y.

Rev Sci Instrum. 2019 Dec 1;90(12):123107. doi: 10.1063/1.5116717.

PMID:
31893849
2.

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.

Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R.

J Hematol Oncol. 2019 Dec 30;12(1):145. doi: 10.1186/s13045-019-0835-1.

3.

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.

Papadopoulos KP, Johnson ML, Lockhart AC, Moore KN, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner R, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR.

Clin Cancer Res. 2019 Dec 3. pii: clincanres.2609.2019. doi: 10.1158/1078-0432.CCR-19-2609. [Epub ahead of print]

PMID:
31796520
4.

Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.

Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N.

Am J Gastroenterol. 2019 Nov 27. doi: 10.14309/ajg.0000000000000398. [Epub ahead of print]

PMID:
31789632
5.

Factors affecting symptom presentation in an early-phase clinical trials clinic patient population.

George GC, Mendoza TR, Iwuanyanwu EC, Manandhar M, Afshar SF, Piha-Paul SA, Tsimberidou A, Naing A, Cleeland CS, Hong DS.

Invest New Drugs. 2019 Nov 25. doi: 10.1007/s10637-019-00879-0. [Epub ahead of print]

PMID:
31761957
6.

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.

Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS.

Cancer Immunol Res. 2019 Dec;7(12):1903-1909. doi: 10.1158/2326-6066.CIR-18-0793. Epub 2019 Oct 28.

PMID:
31658994
7.

Tomato seeds pretreated with Antifreeze protein type I (AFP I) promotes the germination under cold stress by regulating the genes involved in germination process.

Kyu SY, Naing AH, Pe PPW, Park KI, Kim CK.

Plant Signal Behav. 2019;14(12):1682796. doi: 10.1080/15592324.2019.1682796. Epub 2019 Oct 24.

PMID:
31647356
8.

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.

Autio KA, Boni V, Humphrey RW, Naing A.

Clin Cancer Res. 2019 Oct 10. doi: 10.1158/1078-0432.CCR-19-1457. [Epub ahead of print] Review.

PMID:
31601568
9.

Silencing of the phytoene desaturase (PDS) gene affects the expression of fruit-ripening genes in tomatoes.

Naing AH, Kyu SY, Pe PPW, Park KI, Lee JM, Lim KB, Kim CK.

Plant Methods. 2019 Oct 4;15:110. doi: 10.1186/s13007-019-0491-z. eCollection 2019.

10.

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM.

Lancet Oncol. 2019 Nov;20(11):1544-1555. doi: 10.1016/S1470-2045(19)30514-5. Epub 2019 Sep 25. Erratum in: Lancet Oncol. 2019 Dec;20(12):e663.

PMID:
31563517
11.

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.

Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A.

J Immunother Cancer. 2019 Sep 18;7(1):253. doi: 10.1186/s40425-019-0722-x.

12.

Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors.

Creasy CA, Forget MA, Singh G, Tapia C, Xu M, Stephen B, Sabir S, Meric-Bernstam F, Haymaker C, Bernatchez C, Naing A.

Eur J Immunol. 2019 Dec;49(12):2245-2251. doi: 10.1002/eji.201948217. Epub 2019 Sep 30.

PMID:
31532833
13.

The role of antifreeze proteins in the regulation of genes involved in the response of Hosta capitata to cold.

Pe PPW, Naing AH, Chung MY, Park KI, Kim CK.

3 Biotech. 2019 Sep;9(9):335. doi: 10.1007/s13205-019-1859-5. Epub 2019 Aug 17.

PMID:
31475087
14.

A brief review of applications of antifreeze proteins in cryopreservation and metabolic genetic engineering.

Naing AH, Kim CK.

3 Biotech. 2019 Sep;9(9):329. doi: 10.1007/s13205-019-1861-y. Epub 2019 Aug 12. Review.

PMID:
31448185
15.

Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].

Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V.

Lung Cancer. 2019 Oct;136:158. doi: 10.1016/j.lungcan.2019.08.017. Epub 2019 Aug 21. No abstract available.

PMID:
31445783
16.

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.

Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M.

J Immunother Cancer. 2019 Aug 22;7(1):225. doi: 10.1186/s40425-019-0665-2.

17.

A new screening tool for FGFR inhibitor treatment?

Naing A.

Lancet Oncol. 2019 Oct;20(10):1340-1342. doi: 10.1016/S1470-2045(19)30490-5. Epub 2019 Aug 9. No abstract available.

PMID:
31405821
18.

CRISPR/Cas9-mediated editing of 1-aminocyclopropane-1-carboxylate oxidase1 enhances Petunia flower longevity.

Xu J, Kang BC, Naing AH, Bae SJ, Kim JS, Kim H, Kim CK.

Plant Biotechnol J. 2020 Jan;18(1):287-297. doi: 10.1111/pbi.13197. Epub 2019 Jul 2.

19.

Complementary and Integrative Medicine Use in Individuals Seeking Conventional Medical Oncology Care in Chile: Prevalence and Patient Characteristics.

Lopez G, Salas CA, Cadiz F, Barriga C, Gonzalez P, Acevedo S, Raimilla P, Pincheira P, Naing A, Quiroga M.

J Glob Oncol. 2019 May;5:1-6. doi: 10.1200/JGO.18.00190.

20.

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.

Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.

J Immunother Cancer. 2019 May 3;7(1):118. doi: 10.1186/s40425-019-0604-2.

21.

In vitro propagation method for production of morphologically and genetically stable plants of different strawberry cultivars.

Naing AH, Kim SH, Chung MY, Park SK, Kim CK.

Plant Methods. 2019 Apr 13;15:36. doi: 10.1186/s13007-019-0421-0. eCollection 2019.

22.

Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors.

Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C.

Am J Cardiol. 2019 Apr 15;123(8):1351-1357. doi: 10.1016/j.amjcard.2019.01.013. Epub 2019 Jan 25.

PMID:
30765065
23.

Transcriptional activation of anthocyanin structural genes in Torenia 'Kauai Rose' via overexpression of anthocyanin regulatory transcription factors.

Junping X, Naing AH, Kim CK.

3 Biotech. 2018 Nov;8(11):476. doi: 10.1007/s13205-018-1505-7. Epub 2018 Nov 10.

24.

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.

Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M.

Cancer Cell. 2018 Nov 12;34(5):775-791.e3. doi: 10.1016/j.ccell.2018.10.007.

25.

Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.

Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP.

Am J Gastroenterol. 2019 Feb;114(2):250-257. doi: 10.1038/s41395-018-0383-2.

PMID:
30410039
26.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
27.

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A.

Gynecol Oncol. 2018 Dec;151(3):407-413. doi: 10.1016/j.ygyno.2018.10.008. Epub 2018 Oct 24.

28.

Overexpression of RsMYB1 Enhances Anthocyanin Accumulation and Heavy Metal Stress Tolerance in Transgenic Petunia.

Ai TN, Naing AH, Yun BW, Lim SH, Kim CK.

Front Plant Sci. 2018 Sep 20;9:1388. doi: 10.3389/fpls.2018.01388. eCollection 2018.

29.

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.

Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S.

Oncotarget. 2018 Sep 7;9(70):33258-33270. doi: 10.18632/oncotarget.25947. eCollection 2018 Sep 7.

30.

Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience.

Yalcin S, Hurmuz P, McQuinn L, Naing A.

J Glob Oncol. 2018 Sep;4:1-6. doi: 10.1200/JGO.2016.008896. Epub 2017 Apr 18.

31.

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS.

Oncotarget. 2018 Sep 4;9(69):33232-33243. doi: 10.18632/oncotarget.26075. eCollection 2018 Sep 4.

32.

Biomarkers of response to immune checkpoint blockade in cancer treatment.

Fujii T, Naing A, Rolfo C, Hajjar J.

Crit Rev Oncol Hematol. 2018 Oct;130:108-120. doi: 10.1016/j.critrevonc.2018.07.010. Epub 2018 Aug 3. Review.

PMID:
30196907
33.

Enhancement of Low pH Stress Tolerance in Anthocyanin-Enriched Transgenic Petunia Overexpressing RsMYB1 Gene.

Naing AH, Lee DB, Ai TN, Lim KB, Kim CK.

Front Plant Sci. 2018 Aug 21;9:1124. doi: 10.3389/fpls.2018.01124. eCollection 2018.

34.

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM.

Cancer Chemother Pharmacol. 2018 Nov;82(5):877-885. doi: 10.1007/s00280-018-3680-y. Epub 2018 Sep 4.

PMID:
30182147
35.

Differential expression of anthocyanin structural genes and transcription factors determines coloration patterns in gerbera flowers.

Naing AH, Park DY, Park KI, Kim CK.

3 Biotech. 2018 Sep;8(9):393. doi: 10.1007/s13205-018-1408-7. Epub 2018 Aug 30.

36.

Roles of R2R3-MYB transcription factors in transcriptional regulation of anthocyanin biosynthesis in horticultural plants.

Naing AH, Kim CK.

Plant Mol Biol. 2018 Sep;98(1-2):1-18. doi: 10.1007/s11103-018-0771-4. Epub 2018 Aug 30. Review.

PMID:
30167900
37.

Overexpression of Rosea1 From Snapdragon Enhances Anthocyanin Accumulation and Abiotic Stress Tolerance in Transgenic Tobacco.

Naing AH, Ai TN, Lim KB, Lee IJ, Kim CK.

Front Plant Sci. 2018 Aug 15;9:1070. doi: 10.3389/fpls.2018.01070. eCollection 2018.

38.

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML.

Clin Cancer Res. 2018 Aug 15;24(16):3845-3856. doi: 10.1158/1078-0432.CCR-17-2707. Epub 2018 Jul 17.

39.

Challenges for Migrant and Cross-Border Populations With Diabetes Mellitus at Mae Tao Clinic in the Mae Sot-Myawaddy Border Region of Thailand and Myanmar.

Naing AL, Bakker M.

Int J Low Extrem Wounds. 2018 Sep;17(3):195-196. doi: 10.1177/1534734618788928. Epub 2018 Jul 16.

PMID:
30012032
40.

Anti-freezing-protein type III strongly influences the expression of relevant genes in cryopreserved potato shoot tips.

Seo JH, Naing AH, Jeon SM, Kim CK.

Plant Mol Biol. 2018 Jul;97(4-5):347-355. doi: 10.1007/s11103-018-0743-8. Epub 2018 Jun 4.

PMID:
29869190
41.

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V.

Lung Cancer. 2018 Jun;120:137-141. doi: 10.1016/j.lungcan.2018.03.020. Epub 2018 Apr 11. Erratum in: Lung Cancer. 2019 Oct;136:158.

42.

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D.

Br J Cancer. 2018 May;118(11):1419-1424. doi: 10.1038/s41416-018-0068-z. Epub 2018 Apr 26.

43.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

44.

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.

Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F.

Ann Oncol. 2018 Jun 1;29(6):1445-1453. doi: 10.1093/annonc/mdy119.

45.

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.

Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V.

Br J Cancer. 2018 Mar 20;118(6):763-769. doi: 10.1038/bjc.2017.480. Epub 2018 Feb 20.

46.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

47.

Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression.

Pucci M, Reclusa Asiáin P, Duréndez Sáez E, Jantus-Lewintre E, Malarani M, Khan S, Fontana S, Naing A, Passiglia F, Raez LE, Rolfo C, Taverna S.

Target Oncol. 2018 Apr;13(2):175-187. doi: 10.1007/s11523-018-0551-8. Review.

PMID:
29374391
48.

Transcriptional control of anthocyanin biosynthesis genes and transcription factors associated with flower coloration patterns in Gerbera hybrida.

Naing AH, Lee JH, Park KI, Kim KO, Chung MY, Kim CK.

3 Biotech. 2018 Jan;8(1):65. doi: 10.1007/s13205-018-1099-0. Epub 2018 Jan 12.

49.

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V.

J Immunother Cancer. 2017 Dec 19;5(1):100. doi: 10.1186/s40425-017-0301-y.

50.

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F.

Mol Cancer Ther. 2018 Mar;17(3):671-676. doi: 10.1158/1535-7163.MCT-17-0673. Epub 2017 Dec 13.

Supplemental Content

Support Center